AARTIPHARM
Aarti Pharmalabs Limited (AARTIPHARM) breaks out, moves up 5% intraday
Aarti Pharmalabs Limited (NSE: AARTIPHARM) stock price hits ₹712.95, clearing its 6M resistance trendline with a 5% intraday gain. .
Aarti Pharmalabs Limited (AARTIPHARM) breaks out, gaining +5% to ₹712.95 on the NSE on 23 Jun 2026. The stock cleared its 6M resistance trendline, moving above ₹592 with a 17.0% margin. This move comes after Chandrakant Vallabhaji Gogri submitted a disclosure under SEBI Takeover Regulations, potentially signaling increased interest in the company. Aarti Pharmalabs, a mid-cap player in the specialty and generic drug manufacturing sector, shows a move that appears company-specific rather than a sector-wide trend.
Technical setup — trendlines & DMA
The current 6M trendline structure shows a breakout above the resistance at ₹591.51, with today’s price sitting 17.03% above this level. The 6M support trendline ends at ₹619.85, which is 13.06% below the current price. The 50-DMA at ₹690.3 is below the 200-DMA at ₹739.1, indicating a bearish trend, though the stock is showing momentum as it has broken above both moving averages. In the 52W range of ₹585.0–₹971.0, the current price is in the middle third, suggesting that while there is room for further upside, a significant portion of the move might already be priced in.
Snapshot: ₹712.95 on 2026-06-23 (chart frozen at publication)
Fundamentals & business context
With a PE of 35.3, profit margins at 9.6%, and a revenue CAGR of -2.0%, Aarti Pharmalabs’ valuation appears stretched relative to its current earnings. The market might be pricing in a turnaround, given the company’s ambitious growth targets. Institutional ownership stands at 12.5%, indicating a cautious but present interest from smart money. There is no specific NSE catalyst today beyond the SEBI disclosure, which might be contributing to the breakout.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak position. The strongest signals include the breakout above resistance levels with momentum, and very low debt with a D/E of 0.21, indicating excellent financial health. On the weaker side, the company shows declining revenue and profit CAGRs at -2.0% and -3.3% respectively, and a low profit margin of 9.6%, which leaves thin profits and little room for error. Additionally, the stock has declined 20.8% in the last year, and bearish sentiment prevails with more down days than up days in the last 30 days.
Company outlook
Aarti Pharmalabs is targeting 15% to 18% growth in both revenue and EBITDA for the next three to four years. For FY 2027, the company expects the CDMO/CMO business to lead growth with a projected sales increase of 40% to 50% per annum. The API and intermediate business is also anticipated to show Y-o-Y growth in FY 2027. The company aims for the CDMO segment to reach ₹1000 Crores in revenue by FY 2028 or max by FY 2029. Management expects EBITDA contribution from capex to start materializing from the second half of the year. The company plans to maintain similar spending levels for FY 2027, including ongoing expansions and possible new production blocks.
Get all details on AARTIPHARM — P&L, peers, shareholding and more on TradeAlone.
AARTIPHARM
Aarti Pharmalabs Limited (AARTIPHARM) clears resistance, gains 11% intraday
Aarti Pharmalabs Limited (NSE: AARTIPHARM) stock price moves up 11% intraday to ₹917.5, breaking out from its 6-month resistance trendline.
Aarti Pharmalabs Limited (AARTIPHARM) breaks out with an 11% surge to ₹917.5 on the NSE, clearing its 6-month resistance trendline. This move follows the company’s recent corporate announcements, including an investor presentation and analyst meet updates, which likely fueled positive sentiment. Aarti Pharmalabs, a mid-cap player in the specialty and generic drug manufacturing sector, shows a company-specific rally rather than broad sector momentum, indicating unique catalysts at play.
Technical setup — trendlines & DMA
The stock’s current 6-month trendline structure shows a breakout above the resistance at ₹707, now 22.9% higher, and a robust 29.3% above the support trendline at ₹648.71. The 50-DMA at ₹676.0 is below the 200-DMA at ₹710.8, typically a bearish signal, but the stock is currently 21.75% above the 50-DMA, indicating an extended move. Aarti Pharmalabs is trading in the upper third of its 52-week range, 92% above the low and just 3% below the high, suggesting much of the potential upside may already be priced in.
Snapshot: ₹917.50 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
With a PE of 42.7 and profit margins at 10.4%, Aarti Pharmalabs’ valuation appears stretched given its declining 5-year revenue CAGR of -2.0% and profit CAGR of -3.3%. This suggests the market may be pricing in a turnaround or future growth not yet reflected in current earnings. Institutional ownership stands at 12.5%, indicating a cautious but present interest from smart money. There was no specific NSE catalyst today, but the recent corporate announcements likely contributed to the positive sentiment.
Algorithmic scorecard
Aarti Pharmalabs presents a technically strong but fundamentally weak profile. The breakout above resistance and strong bullish sentiment over the last 30 days, with volume running 2.36x heavier on up days, signal accumulation and positive momentum. However, the declining revenue and profit CAGRs, coupled with negligible dividend yield, highlight underlying business challenges. The stock’s overbought RSI at 75.6 and the bearish trend indicated by the 50-DMA below the 200-DMA suggest caution is warranted despite the recent rally.
Company outlook
Aarti Pharmalabs is targeting 15% to 18% growth in both revenue and EBITDA over the next three to four years. For the immediate fiscal year 2027, the company expects its CDMO/CMO business to lead growth with a projected sales increase of 40% to 50% per annum. The API and intermediate business is also anticipated to show year-over-year growth in FY 2027. The company plans for the CDMO segment to reach Rs.1000 Crores in revenue by FY 2028 or at the latest by FY 2029. Additionally, Aarti Pharmalabs expects EBITDA contribution from its capex to begin materializing in terms of margin expansion from the second half of the year. The company intends to maintain similar spending levels for FY 2027, including ongoing expansions and possible new production blocks, with an additional tentative spend of Rs.400 Crores for future projects.
Get all details on AARTIPHARM — P&L, peers, shareholding and more on TradeAlone.
AARTIPHARM
Aarti Pharmalabs Limited (AARTIPHARM) breaks out, gains 9% intraday
Aarti Pharmalabs Limited (NSE: AARTIPHARM) stock price gains 9% intraday, breaking out from its 6-month resistance trendline. Current price stands at ₹900.2.
Aarti Pharmalabs Limited (AARTIPHARM) breaks out, gaining +9% to ₹900.2 on the NSE on 11 Aug 2026. This surge follows the stock clearing its 6M resistance trendline, marking a transition from a bounce from support to a breakout phase. In the healthcare sector, Aarti Pharmalabs specializes in drug manufacturing, and today’s move appears to be driven by company-specific factors rather than broader sector momentum.
Technical setup — trendlines & DMA
Currently, the 6M support trendline stands at ₹648.71, significantly below the current price, indicating a robust upward move. Resistance was previously at ₹707.0, which the stock has now surpassed by 21.46%, solidifying the breakout. The 50-DMA at ₹676.0 and the 200-DMA at ₹710.8 both lie below the current price, suggesting the stock is extended but has momentum. Within the 52W range of ₹585.0–₹946.1, the stock is in the upper third, reflecting a strong performance though still below the 52W high, leaving room for further upside or potential pullback.
Snapshot: ₹900.20 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
With a PE of 42.7 and profit margins at 10.4%, Aarti Pharmalabs’ valuation appears stretched given its recent revenue CAGR of -2.0% and profit CAGR of -3.3%. This suggests the market may be pricing in anticipated improvements or a turnaround, which the current stock performance seems to reflect. Institutional holding at 12.5% indicates a cautious yet present interest from smart money, though not overwhelmingly bullish. There was no specific NSE catalyst today, but the breakout and positive sentiment likely play a role in the stock’s performance.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile for Aarti Pharmalabs. Two of the strongest signals are the breakout above resistance levels with momentum and the bullish sentiment over the last 30 days, where volume on up days ran 2.36x heavier than on down days, indicating systematic accumulation. Conversely, the two weakest signals are the declining revenue and profit CAGRs, which pose risks to sustained growth, and the negligible dividend yield, offering little income to offset potential stock volatility.
Company outlook
Aarti Pharmalabs is targeting 15% to 18% growth in both revenue and EBITDA for the next three to four years. For the immediate fiscal year 2027, the company expects the CDMO/CMO business to lead growth with a projected sales growth of 40% to 50% per annum. The company anticipates year-over-year growth for the API and intermediate business in FY 2027 and expects the CDMO segment to reach Rs.1000 Crores in revenue by FY 2028 or max by FY 2029. Additionally, the company plans to maintain a similar level of spending for FY 2027, including ongoing expansions and possible new production blocks, with an additional tentative spend of Rs.400 Crores going forward.
Get all details on AARTIPHARM — P&L, peers, shareholding and more on TradeAlone.
AARTIPHARM
Aarti Pharmalabs Limited (AARTIPHARM) breaks out, moves up 20% intraday
Aarti Pharmalabs Limited (NSE: AARTIPHARM) stock price gains 20% intraday, clearing its 6-month resistance trendline at ₹707.
Aarti Pharmalabs Limited (AARTIPHARM) breaks out with a +20% surge to ₹823.0 on the NSE on 10 Aug 2026, clearing its 6-month resistance trendline. This move follows the company’s announcement of capacity addition, signaling potential growth ahead. Aarti Pharmalabs, a mid-cap player in the specialty and generic drug manufacturing sector, has shown a company-specific move today, diverging from the broader sector’s momentum.
Technical setup — trendlines & DMA
From a technical standpoint, Aarti Pharmalabs has broken above its 6-month resistance trendline, which ended at ₹707.0, now trading 14.09% above this level. The stock is also comfortably above its 6-month support trendline at ₹648.71, indicating a solid base. The 50-DMA at ₹674.2 is slightly below the 200-DMA at ₹712.2, suggesting a bearish trend, but the recent breakout indicates potential reversal. The stock is currently in the middle third of its 52-week range, suggesting room for further upside if the breakout sustains.
Snapshot: ₹823.00 on 2026-08-10 (chart frozen at publication)
Fundamentals & business context
Fundamentally, Aarti Pharmalabs presents a mixed picture. With a PE of 35.1 and profit margins at 9.6%, the valuation appears stretched given the company’s revenue CAGR of -2.0% and profit CAGR of -3.3% over the past five years. However, the market may be pricing in the company’s growth outlook, particularly in its CDMO/CMO business, which is expected to drive significant revenue growth. Institutional ownership stands at 12.5%, indicating some level of confidence from smart money, though not overwhelmingly so. There was no specific NSE catalyst today beyond the capacity addition announcement.
Algorithmic scorecard
The algorithmic scorecard reflects a technically strong but fundamentally weak profile for Aarti Pharmalabs. Two of the strongest signals are the very low debt level, with a D/E ratio of 0.21, indicating excellent financial health, and the significant public holding of 35.92%, suggesting moderate retail influence and liquidity. On the weaker side, the company’s low profit margin of 9.6% leaves little room for error, and the negligible dividend yield of 0.58% offers little income for investors. These factors highlight the risks associated with the stock’s valuation and growth prospects.
Company outlook
Management has outlined an ambitious growth trajectory for Aarti Pharmalabs, targeting 15% to 18% growth in both revenue and EBITDA for the next three to four years. For the immediate fiscal year 2027, the company expects its CDMO/CMO business to lead growth with a projected sales increase of 40% to 50% per annum. The API and intermediate business is also anticipated to show year-over-year growth in FY 2027. The company aims for its CDMO segment to reach ₹1000 Crores in revenue by FY 2028 or at the latest by FY 2029. To support this growth, Aarti Pharmalabs plans to maintain a similar level of spending for FY 2027, including ongoing expansions and possible new production blocks, with an additional tentative spend of ₹400 Crores going forward.
Get all details on AARTIPHARM — P&L, peers, shareholding and more on TradeAlone.
-
Basic Materials3 days agoThe Ramco Cements Limited (ramcocem) Wins Three Honours at Kyoorius Design Awards 2026
-
GAIL3 days agoGail (india) Limited Appoints Shri Manoj Kumar Sharma as Director (projects)
-
Basic Materials3 days agoSteel Authority of India Limited (sail) FY’27 Snapshot: Robust Financials and Production Metrics
-
COFORGE2 days agoCoforge Limited (NSE: Coforge) Expands Ai-powered Vehicle Lifecycle Intelligence Capabilities
-
Industrials3 days agoTirupati Forge Limited Secures Strategic Industrial License Under Indian Arms Act for Artillery Shell Manufacturing
-
GODREJPROP3 days agoGodrej Properties Limited (godrejprop) Constructs 24-metre-wide Government Road in Gurugram
-
Information Technology Services21 hours agoPersistent Systems Limited (persistent) Earns Databricks Brickbuilder Specialization for BFSI
-
PREMIERENE1 day agoPremier Energies Limited (premierene) Commissions India’s Largest Solar Cell Facility